Glucagon anticorps

N° du produit ABIN7181328

Détail du produit anti-Glucagon anticorps

Antigène: Glucagon (GCG)

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Glucagon est non-conjugé

Application: ELISA, Immunohistochemistry (IHC)

Réactivité croisée: Humain

Purification: Affinity purified

Immunogène: Synthesized peptide derived from human Glucagon

Isotype: IgG2b kappa

Information d'application

Indications d'application: Recommended dilution: IHC:1:20-1:200,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur Glucagon

Antigène: Glucagon (GCG)

Autre désignation: GCG (GCG Produits)

Synonymes: anticorps GLP1, anticorps GLP2, anticorps GRPP, anticorps GLP-1, anticorps Glu, anticorps PPG, anticorps GCG, anticorps gcg-A, anticorps gcg1, anticorps glucagon, anticorps glucagon L homeolog, anticorps GCG, anticorps Gcg, anticorps gcg.L

Sujet:

Background: Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis. GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.

Edoardo C. Aromataris, J. Physiol., Jun 2006, 573: 611 - 625.
Xiao C. Li, Hypertension, Mar 2006, 47: 580 - 585.
Kirstan A. Vessey, Invest. Ophthalmol. Vis. Sci., Nov 2005, 46: 3922 - 3931.
Xiaosong Ma, Mol. Endocrinol., Jan 2005, 19: 198 - 212.

Aliases: Glicentin, Glicentin-related polypeptide, Oxyntomodulin, Glucagon-like peptide 1(GLP-1), Glucagon-like peptide 1(7-37)

UniProt: P01275

Pathways: Positive Regulation of Peptide Hormone Secretion, Peptide Hormone Metabolism, cAMP Metabolic Process, Regulation of Carbohydrate Metabolic Process, Feeding Behaviour, Negative Regulation of intrinsic apoptotic Signaling